ScreenerHero

HCM HUTCHMED (China) Limited

LSE · GB · Healthcare · Drug Manufacturers - Specialty & Generic · hutch-med.com
214.00GBp-0.47%Mkt Cap: 2.02B $P/E: 214.00

HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies to treat cancer and immunological diseases in Hong Kong, the United States, and …

Industry Peers

Drug Manufacturers - Specialty & Generic
Screen all
MRK
Merck KGaA
$64.30BUSDP/E 25.0
TAK
Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)
$57.06BUSD
TEVA
Teva Pharmaceutical Industries Limited Ordinary Shares
$46.10BUSDP/E 65.9
HLN
Haleon plc American Depositary Shares (Each representing two Ordinary Shares)
$38.70BUSDP/E 18.3
ZOE
Zoetis Inc.
$28.27BUSDP/E 12.1
ZTS
Zoetis Inc. Class A Common Stock
$28.80BUSDP/E 11.4
UTHR
United Therapeutics Corporation - Common Stock
$23.23BUSDP/E 19.4
VTRS
Viatris Inc. - Common Stock
$20.22BUSD
SOBI
Swedish Orphan Biovitrum AB (publ)
$14.14BUSDP/E 110.6
NBIX
Neurocrine Biosciences, Inc. - Common Stock
$14.55BUSDP/E 21.0
IPN
Ipsen S.A.
$12.60BUSDP/E 22.8
ELAN
Elanco Animal Health Incorporated Common Stock
$11.06BUSD
RDY
Dr. Reddy's Laboratories Ltd Common Stock
$10.20BUSDP/E 29.2
KRK
Krka, d. d.
$8.59BUSDP/E 19.2
AMRX
Amneal Pharmaceuticals, Inc. - Class A Common Stock
$7.07BUSDP/E 42.3
ALKS
Alkermes plc - Ordinary Shares
$7.00BUSDP/E 109.9
HIMS
Hims & Hers Health, Inc. Class A Common Stock
$6.77BUSD
LNTH
Lantheus Holdings, Inc. - Common Stock
$6.53BUSDP/E 23.9
KNSA
Kiniksa Pharmaceuticals International, plc - Class A Ordinary Shares
$5.83BUSDP/E 76.6
INDV
Indivior Pharmaceuticals, Inc. - Common Stock
$4.21BUSDP/E 12.8

Key Statistics

Company
Market Cap2.02B USD
Enterprise Value652.99M USD
Revenue (TTM)596.87M USD
Gross Profit230.61M USD
Net Income (TTM)496.64M USD
Revenue/Share0.64 GBp
Last Price214.00 GBp
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees1.8K
CountryGB
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
ISIN—
Valuation
P/E (Trailing)214.00
P/E (Forward)40.93
PEG—
EV/EBITDA-29.28
EV/Revenue1.09
P/S3.40
P/B1.98
EPS (TTM)0.01
EPS (Forward)0.05
52W Range
150.4866% of range247.30
52W High247.30 GBp
52W Low150.48 GBp
Profitability
Gross Margin38.68%
Oper. Margin0.31%
EBITDA Margin-3.74%
Profit Margin83.30%
ROE36.91%
ROA26.06%
Growth
Revenue Growth0.20%
Earnings Growth-96.50%
Cash Flow & Leverage
Operating CF-70.28M USD
CapEx (TTM)26.25M USD
FCF Margin-3.44%
FCF Yield-1.02%
Net Debt-1.39B USD
Net Debt/EBITDA62.49
Balance Sheet
Debt/Equity0.08
Current Ratio5.64
Quick Ratio5.45
Book Value/Sh1.08 GBp
Cash/Share1.58 GBp
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 GBp
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split10:1
Split DateMay 30, 2019
Analyst Consensus
Rating1.5 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)345.85 GBp
Upside (mean)+61.6%
Target Range221.37 GBp – 531.72 GBp
221.37+61.6% to mean531.72
# Analysts7
Ownership
Shares Out.869.07M
Float522.84M
Insiders38.80%
Institutions20.12%
Technical
SMA 50192.79 (+11.0%)
SMA 200196.44 (+8.9%)
Beta0.45
S&P 52W Chg14.58%
Avg Vol (30d)59.13K
Avg Vol (10d)43.15K
Technical Indicators
RSI (14)56.6
MACD8.0616
MACD Signal7.8001
MACD Hist.+0.2615
BB Upper227.45 GBp
BB Middle209.35 GBp
BB Lower191.25 GBp
BB Width17.29%
ATR (14)10.44 GBp
Vol Ratio (20d)0.33x